NCT07396168 is a Phase 4 clinical trial of Nemolizumab in Lichen Plano-Pilaris, sponsored by The Skin Center Dermatology Group.

Who is sponsoring NCT07396168?

NCT07396168 is sponsored by The Skin Center Dermatology Group.

What drugs are being tested in NCT07396168?

Interventions in NCT07396168: Nemolizumab.

What condition does NCT07396168 study?

NCT07396168 studies Lichen Plano-Pilaris.

Is NCT07396168 still recruiting?

NCT07396168 is currently recruiting now. Last updated 7 February 2026.

Last reviewed 2026-02-07 · How we verify

NCT07396168

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Nemolizumab to Treat Lichen Planopilaris, a Noncontrolled, Prospective, Pilot Study.

Recruiting now Phase 4 Last updated 7 February 2026

What this trial tests

Phase 4 trial testing Nemolizumab in Lichen Plano-Pilaris in 10 participants. Currently enrolling.

Timeline

1 February 2026

Primary endpoint
1 June 2027

1 June 2027

Quick facts

Lead sponsor	The Skin Center Dermatology Group
Phase	Phase 4
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	10
Start date	1 February 2026
Primary completion	1 June 2027
Estimated completion	1 June 2027
Sites	1 location across United States

Drugs / interventions tested

Nemolizumab (NEMOLIZUMAB) — full drug profile →

Conditions studied

Lichen Plano-Pilaris — all drugs for Lichen Plano-Pilaris →

Sponsor

The Skin Center Dermatology Group

Who can join

18 and older, any sex, with Lichen Plano-Pilaris. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Change from baseline at 24 weeks in Lichen Planopilaris Activity Index (LPPAI)
Time frame: 24 weeks
Change from baseline at 24 weeks in Investigator Global Assessment (IGA) score (scarring alopecia version)
Time frame: 24 weeks

Sponsor's own description

Lichen planopilaris (LPP) is a primary lymphocytic cicatricial alopecia characterized by progressive, permanent hair loss and scalp symptoms such as pruritus and burning. Current treatments-including topical and intralesional corticosteroids, hydroxychloroquine, and immunosuppressants-are often inadequate, with limited evidence for efficacy and frequent treatment switching or discontinuation due to side effects or lack of response.1,2 Recent systematic reviews and meta-analyses highlight the need for new, targeted therapies. 3,4 Nemolizumab, an IL-31 receptor antagonist, FDA-approved for prurigo nodularis and atopic dermatitis, has demonstrated efficacy in pruritic and fibrosing dermatoses, making it a rational candidate for LPP.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Nemolizumab

Trials testing the same drug.

NCT07047690 — A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis · Phase 2 · recruiting
NCT07352566 — Utilization of a Microdevice for Psoriasis and Atopic Dermatitis · Phase 4 · not yet recruiting
NCT05405985 — Study to Access the Relative Bioavailability of Subcutaneous Dose of Nemolizumab When Administered Via Auto-Injector Ver · Phase 1 · completed
NCT05052983 — A Study to Evaluate the Durability of Response and Safety of Nemolizumab for 24 Weeks in Participants With Prurigo Nodul · Phase 3 · completed
NCT05075408 — To Evaluate the Efficacy and Safety of Nemolizumab for 12 Weeks in Participants With Chronic Kidney Disease With Associa · Phase 2, PHASE3 · completed

Other The Skin Center Dermatology Group trials

Trials by the same sponsor.

NCT06791525 — Tirbanibulin for Pediatric Warts · Phase 4 · recruiting
NCT05592548 — Rosacea Treatment Using Non-thermal (Cold) Atmospheric Plasma Device · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07396168 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The Skin Center Dermatology Group
Last refreshed: 7 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07396168.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing